文献速递淋巴瘤

血浆蛋白质组学在特发性多中心Castleman病中鉴定出「趋化因子风暴」

Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.
PubMed 文献 · Am J Hematol · 2018-05-16

本研究对6例特发性多中心Castleman病(iMCD)患者发作期与缓解期的13份血浆样本定量1129种蛋白质,发现趋化因子和补体通路显著富集,CXCL13为上调最显著的细胞因子(log2倍数变化=3.22),提示iMCD涉及「趋化因子风暴」,并观察到TAFRO亚型与NOS亚型间蛋白质组差异。

要点

  • iMCD发作期血浆中趋化因子和补体通路显著富集,趋化因子占上调细胞因子比例最大。
  • CXCL13在所有患者中上调最显著(log2倍数变化=3.22),淋巴结生发中心CXCL13表达亦显著增加。
  • 两例TAFRO患者均对anti-IL-6治疗无应答,四例NOS患者中三例治疗均应答,提示机制差异。

核心结论

  • iMCD发作期与缓解期存在蛋白质组差异,趋化因子和补体通路显著富集,提示iMCD涉及「趋化因子风暴」。
  • CXCL13是上调最显著的细胞因子,在iMCD淋巴结生发中心也显著增高。
  • TAFRO与NOS亚型间蛋白质组谱不同,提示可能存在不同机制,并有望在分子层面定义iMCD亚组。

研究设计与样本

  • 对6例iMCD患者发作期和缓解期的13份血浆样本定量1129种蛋白质。
  • 比较iMCD淋巴结生发中心与对照的CXCL13表达。
  • 比较2例TAFRO患者与4例NOS患者的蛋白质组谱。

主要发现

  • 急性期反应物NPS-PLA2是唯一显著升高的蛋白质(P = .017)。
  • 趋化因子和补体为显著富集的通路,趋化因子占上调细胞因子比例最大。
  • CXCL13在所有患者中上调最显著(log2倍数变化 = 3.22)。
  • iMCD淋巴结生发中心CXCL13表达较对照显著增加,呈基质网状模式。
  • 2例TAFRO患者均对anti-IL-6治疗无应答,4例NOS患者中3例接受anti-IL-6治疗均应答。

关键数值与推荐

  • 发作期与缓解期血浆中NPS-PLA2显著升高(P = .017)。
  • CXCL13 log2倍数变化 = 3.22。
  • 2例TAFRO患者均anti-IL-6治疗失败,4例NOS患者中3例治疗均应答。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Human Herpesvirus-8 (HHV-8)-negative/idiopathic multicentric Castleman disease (iMCD) is a poorly understood disease involving polyclonal lymphoproliferation with dysmorphic germinal centers, constitutional symptoms, and multi-organ failure. Patients can experience thrombocytopenia, anasarca, reticulin fibrosis, renal dysfunction, organomegaly, and normal immunoglobulin levels, - iMCD-TAFRO. Others experience thrombocytosis, milder effusions, and hypergammaglobulinemia, -iMCD-Not Otherwise Specified (iMCD-NOS). Though the etiology is unknown in both subtypes, iMCD symptoms and disease progression are believed to be driven by a cytokine storm, often including interleukin-6 (IL-6). However, approximately two-thirds of patients do not respond to anti-IL-6 therapy; alternative drivers and signaling pathways are not known for anti-IL-6 nonresponders. To identify potential mediators of iMCD pathogenesis, we quantified 1129 proteins in 13 plasma samples from six iMCD patients during flare and remission. The acute phase reactant NPS-PLA2 was the only significantly increased protein (P = .017); chemokines and complement were significantly enriched pathways. Chemokines represented the greatest proportion of upregulated cytokines, suggesting that iMCD involves a chemokine storm. The chemokine CXCL13, which is essential in homing B cells to germinal centers, was the most upregulated cytokine across all patients (log2 fold-change = 3.22). Expression of CXCL13 was also significantly increased in iMCD lymph node germinal centers compared to controls in a stromal meshwork pattern. We observed distinct proteomic profiles between the two iMCD-TAFRO patients, who both failed anti-IL-6-therapy, and the four iMCD-NOS patients, in whom all three treated with anti-IL-6-therapy responded, suggesting that differing mechanisms may exist. This study reveals proteomic differences between flare and remission and the potential to molecularly define iMCD subgroups.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Pierson SK, Stonestrom AJ, Shilling D, et al. Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease. Am J Hematol. 2018. PMID: 29675946. doi:10.1002/ajh.25123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。